A Double Blind
Placebo -
Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0 - III Colon or
Rectal Cancer Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)